Dr. Matthew S. Block, MD, PhD
Claim this profileMayo Clinic in Rochester
Studies Skin Cancer
Studies Melanoma
10 reported clinical trials
14 drugs studied
Area of expertise
1Skin Cancer
Stage IV
Stage III
BRAF positive
2Melanoma
Stage IV
Stage III
BRAF positive
Affiliated Hospitals
Clinical Trials Matthew S. Block, MD, PhD is currently running
Dendritic Cell Vaccine + Pembrolizumab
for Ovarian Cancer
This phase I/II trial tests the safety, side effects, best dose, and effectiveness of multi-epitope folate receptor alpha-loaded dendritic cell vaccine (FRalphaDC) with pembrolizumab in treating patients with ovarian, fallopian tube, or primary peritoneal cancer (collectively known as ovarian cancer) that that has come back (after a period of improvement) (recurrent). Ovarian cancer is the most lethal gynecologic malignancy in the United States. While the majority of patients achieve a remission from ovarian cancer with the combination of aggressive cytoreductive surgery and cytotoxic chemotherapy, over 80% of patients develop recurrence within 3 years of completion of treatment. Additional treatments are needed for recurrence, but the standard treatment modalities are non-curative in nature due to the development of drug resistance. As such, there is a great unmet need for treatment strategies that utilize new mechanisms to which drug resistance does not develop. FRalphaDC is a dendritic cell vaccine that is made from the white blood cells collected from a procedure call apheresis. The white blood cells are treated to make dendritic cells, which will then be incubated with peptides, which are pieces of a protein known as "folate receptor alpha" (FRalpha), a protein that is found in high levels on ovarian cancer cells. Dendritic cell vaccines work by boosting the immune system (a system in the body that protect against infection) to recognize and destroy the tumor cells by targeting the FRalpha protein. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving FRalphaDC vaccine with pembrolizumab may be a safe and effective treatment for recurrent ovarian cancer.
Recruiting1 award Phase 1 & 213 criteria
TILT-123 + Pembrolizumab
for Ovarian Cancer
This is an open-label, phase 1, dose-escalation, multicenter and multinational trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with Pembrolizumab, or Pembrolizumab and Pegylated Liposomal Doxorubicin in patients with platinum resistant or refractory ovarian cancer.
Recruiting1 award Phase 110 criteria
More about Matthew S. Block, MD, PhD
Clinical Trial Related7 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Matthew S. Block, MD, PhD has experience with
- Pembrolizumab
- Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine
- Nab-paclitaxel
- Ibrutinib
- STI-3031
- Placebo Administration
Breakdown of trials Matthew S. Block, MD, PhD has run
Skin Cancer
Melanoma
Ovarian Cancer
Peritoneal Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Matthew S. Block, MD, PhD specialize in?
Matthew S. Block, MD, PhD focuses on Skin Cancer and Melanoma. In particular, much of their work with Skin Cancer has involved Stage IV patients, or patients who are Stage III.
Is Matthew S. Block, MD, PhD currently recruiting for clinical trials?
Yes, Matthew S. Block, MD, PhD is currently recruiting for 5 clinical trials in Rochester Minnesota. If you're interested in participating, you should apply.
Are there any treatments that Matthew S. Block, MD, PhD has studied deeply?
Yes, Matthew S. Block, MD, PhD has studied treatments such as Pembrolizumab, Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine, Nab-paclitaxel.
What is the best way to schedule an appointment with Matthew S. Block, MD, PhD?
Apply for one of the trials that Matthew S. Block, MD, PhD is conducting.
What is the office address of Matthew S. Block, MD, PhD?
The office of Matthew S. Block, MD, PhD is located at: Mayo Clinic in Rochester, Rochester, Minnesota 55905 United States. This is the address for their practice at the Mayo Clinic in Rochester.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.